地舒单抗什么人适合用？

Who is suitable for it? Desosumab, also known as denosumab, is indicated for the treatment of bone loss associated with hormone suppression in postmenopausal women with osteoporosis and prostate cancer. It is also used in patients who are currently ineffective or intolerant to other treatments to reduce the patient's risk of fractures.

Desosumab (denosumab) is a bone resorption inhibitor with a unique mechanism of action. It specifically targets receptor activator of nuclear factor kappa B (RANK) ligand, inhibits the activation and development of osteoclasts, reduces bone resorption, and increases bone density. It was first approved for marketing by the European Union in 2010.

Desosumab is a drug that targets the RANK ligand. Compared with the bisphosphonates that have been used clinically, denosumab has the advantage of significantly prolonging the occurrence time of bone damage-related events. It can be administered subcutaneously in clinical practice and is easy to use. Moreover, clinical data shows that the drug does not require monitoring of renal function, while the use of bisphosphonates must be based on The patient's renal function monitoring determines the dosing speed; however, denosumab is currently relatively expensive, and the balance between its long-term efficacy and cost-effectiveness needs to be further confirmed. It is expected that denosumab, a drug that specifically targets RANK ligand inhibitors, can obtain more valuable research results in the treatment of solid tumors and bring new hope to patients with bone metastasis.

In 2018, denosumab (denosumab) was included in the list of overseas new drugs in urgent clinical need (first batch) and entered the fast review channel of the National Medical Products Administration.

On May 23, 2019, China’s National Medical Products Administration announced conditional approval of the import registration application for Denosumab Injection (English name: Denosumab Injection). The drug will be used to treat adults and skeletally mature adolescent patients with unresectable giant cell tumors of bone or whose surgical resection may result in severe functional impairment.

The above is the information about the indications and applicable groups. I hope it will be helpful to you.